semaglutide carries a black-box warning due to animal studies showing thyroid tumors in rodentsthough no human cases have been confirmed in clinical trials
Saxenda has five dosage strengths: 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, and 3 mg
Compounded tirzepatide injection, a dual-action GLP-1/GIP receptor agonist, begins at $289 per month
In addition, GSK-3 upregulation was demonstrated in obesity and insulin resistance (85, 86)
All together, these support the hypothesis of -cell exhaustion at the end road of insulin resistance, consistent with the pathological mechanisms underlying T2D ( In contrast to GLP-1 postprandial levels, which have been consistently reported to increase after RYGB, reports regarding the circulating levels of GIP following MBS are fewer and results have been inconsistent ( The discrepancies in the results across studies regarding the relation between postprandial GIP and GLP-1 levels and WR may be attributed to differences in the criteria used to define suboptimal outcomes, as well as the inclusion of patients with T2D in some analyses
it's combining mechanisms that target different pathways
